mSphere (Aug 2021)
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals
- Debora Stelitano,
- Stuart P. Weisberg,
- Monica P. Goldklang,
- Yun Zhu,
- Francesca T. Bovier,
- Gavreel F. Kalantarov,
- Giuseppe Greco,
- Didier Decimo,
- Gianluigi Franci,
- Michele Cennamo,
- Giuseppe Portella,
- Massimiliano Galdiero,
- Cyrille Mathieu,
- Branka Horvat,
- Ilya N. Trakht,
- Anne Moscona,
- Michael A. Whitt,
- Matteo Porotto
Affiliations
- Debora Stelitano
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Stuart P. Weisberg
- Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Monica P. Goldklang
- Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Yun Zhu
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Francesca T. Bovier
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Gavreel F. Kalantarov
- Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Giuseppe Greco
- Department of Experimental Medicine, University of Campania “Luigi Vanvitelli,” Napoli, Italy
- Didier Decimo
- CIRI, Centre International de Recherche en Infectiologie, Team Immunobiology of the Viral infections, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France
- Gianluigi Franci
- Department of Medicine, Surgery, Dentistry, University of Salerno “Scuola Medica Salernitana,” Salerno, Italy
- Michele Cennamo
- Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
- Giuseppe Portella
- Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
- Massimiliano Galdiero
- Department of Experimental Medicine, University of Campania “Luigi Vanvitelli,” Napoli, Italy
- Cyrille Mathieu
- ORCiD
- CIRI, Centre International de Recherche en Infectiologie, Team Immunobiology of the Viral infections, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France
- Branka Horvat
- ORCiD
- CIRI, Centre International de Recherche en Infectiologie, Team Immunobiology of the Viral infections, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France
- Ilya N. Trakht
- Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Anne Moscona
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- Michael A. Whitt
- Department of Microbiology, Immunology and Biochemistry, Health Science Center, The University of Tennessee, Memphis, Tennessee, USA
- Matteo Porotto
- ORCiD
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
- DOI
- https://doi.org/10.1128/mSphere.00571-21
- Journal volume & issue
-
Vol. 6,
no. 4
Abstract
Assays for rapid biosafety level 2 (BSL2) evaluation of neutralizing properties of antibodies acquired via natural infection or through vaccination is urgently needed. Here, we propose a combinatorial approach in which sera are screened for SARS-CoV-2 spike protein (S) binding using a cell-based immunofluorescent (CBI) assay, and positive samples are further evaluated in a pseudotyped viral multicycle infection-mimicking protocol under BSL2 conditions.
